What a "PDUFA date" actually means

Haverhill Financial Research · Explainer · October 11, 2026

A PDUFA date is the deadline the FDA sets itself to decide on a drug application. The name comes from the Prescription Drug User Fee Act of 1992, under which drug companies pay fees to fund the FDA's review work and the agency, in return, commits to deciding within set timelines. Ten of the twelve dates on our biotech calendar are FDA decisions of this kind.

When a company submits an application, the FDA has 60 days to decide whether it is complete enough to review. If it accepts the application, it assigns a review track, and the date follows from that.

A company can also buy its way onto the faster track. A priority review voucher, awarded for developing drugs for certain rare pediatric or tropical diseases and tradeable between companies, converts a standard review into a priority one. Vertex used one for povetacicept, which put its November 30 decision on the six-month track.

Approval. The FDA approves the drug, along with a label that sets out who it is for and how it is used. The label matters almost as much as the approval: a narrow one can limit sales.

A complete response letter. The FDA declines to approve for now and lists what it needs. That could be another trial, more data, or fixes at a manufacturing plant. Some companies resubmit within months; others never do.

An extension. If the company sends significant new information during the review, the FDA can extend the date by three months. Capricor and Praxis both had this happen in 2026.

Early action. The FDA can decide before the date. The company usually announces either way, often after the market closes.

Some drugs are approved on an early measure that is reasonably likely to predict real benefit, such as a drop in urine protein in kidney disease, rather than on the final outcome. The company then has to confirm the benefit in further trials. Agios and Vertex are both seeking accelerated approval on our current calendar.

For a company with one or two products, the decision can decide whether it has a business. Before the date, the share price reflects the market's odds of approval; afterwards, it reflects the result. That is why a single day can move a biotech stock by half or more in either direction, and why we treat any biotech holding into a PDUFA date as a high-risk position.

A PDUFA date is a deadline, not a coin flip with fixed odds. The trial data, the FDA's earlier comments and any delays all change the picture. Our Biotech Dates to Know calendar lists every date we are tracking, with the detail we would watch on each.

US Food and Drug Administration, PDUFA reauthorization performance goals and procedures; Vertex Pharmaceuticals, Capricor and Praxis Precision Medicines releases cited in our biotech calendar.

Disclosures. Haverhill Financial Research is a publisher of general financial commentary. This article is not personalized investment advice and does not consider any reader's financial situation; readers should do their own research. Nothing here is a recommendation to buy or sell any security. Company figures and guidance can change. The author of this post does not hold positions in the companies named. Data as of October 11, 2026.